The Pathway to Prevention (P2P) for ME/CFS: A Dangerous Process
Gabby Klein gives an overview of the P2P process, shedding light on the pitfalls with advice as to what we can do in protest ...
Discuss the article on the Forums.

Commons Committee criticises lack of transparency in clinical trials

Discussion in 'Other Health News and Research' started by Shell, Sep 19, 2013.

  1. Shell

    Shell Senior Member

    Messages:
    477
    Likes:
    613
    England
    Just came across this report in Pharma Times It seems that "data transparency was a primary concern of the inquiry".
    I have doubts (big ones) about the efficacy of Govt in ensuring good scientific ethics and protocols, but for publically funded trials, yes, they need to be fully reported and published.
    It's pretty bad when people have to put in FOIs to get data that should automatically be published.
     
    Valentijn, Ritto, aimossy and 2 others like this.
  2. Simon

    Simon

    Messages:
    1,814
    Likes:
    6,369
    Monmouth, UK
    They gave qualified support to making raw data available:
    Which is fine, so long as the gatekeeper is genuinely independent and isn't there to prevent uncomfortable findings from emerging. Very often re-analysis will produce findings that challenge the original author's interpretation - and is some ways that is the most valuable thing about making data availalble: scrutiny.
     
    Shell, Valentijn, wdb and 1 other person like this.

See more popular forum discussions.

Share This Page